Baseline demographic | Fibrotic HP (n=281) | IPF (n=603) | P value |
Gender (M: F) | M 41%: F 61%, n=281 | M 74%: F 26%, n=603 | <0.0001* |
Age (in years) | 73 (65–80), n=252 | 75 (70–80), n=580 | 0.0013 |
Smoking status n, (%) | |||
Unknown | 121 | 212 | 0.0015* |
Ex-smoker | 74 (46%) | 246 (63%) | |
Current | 4, (3%) | 8, (2%) | |
Never | 82 (51%) | 137 (35%) | |
FEV1 actual (L) | 1.76 (1.33–2.19), n=220 | 2.14 (1.71–2.49), n=335 | <0.0001 |
FEV1 % predicted | 80 (66–96), n=198 | 85 (74–97), n=340 | 0.0166 |
FVC actual (L) | 2.19 (1.62–2.75), n=218 | 2.64 (2.18–3.18), n=337 | <0.0001 |
FVC % predicted | 79 (65–94), n=198 | 81 (68–95), n=386 | 0.2673 |
TLCO (L) | 3.77 (2.89–5.09), n=168 | 3.75 (2.93–4.77), n=258 | 0.4556 |
TLCO (% predicted) | 50 (43–64), n=163 | 49 (39–60), n=286 | 0.0296 |
GAP stage | |||
I | 62% | 18% | <0.0001* |
II | 35% | 68% | |
III | 3% | 14% | |
Peripheral monocyte K/uL | 0.60 (0.45–0.77), n=227 | 0.70 (0.54–0.82), n=530 | <0.0001 |
NLR | 2.92 (2.08–4.50), n=226 | 2.78 (2.06–4.08), n=530 | 0.2441 |
CRP | 4 (2–11), n=147 | 4 (2–8), n=220 | 0.4171 |
All values presented as median with IQR, analysed with Mann Whitney U, unless otherwise stated. p<0.05 was considered statistically significant.
*Fisher’s exact test.
%, percentage; CRP, C reactive protein; F, female; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HP, hypersensitivity pneumonitis; IPF, idiopathic pulmonary fibrosis; L, litres ; M, male; n, number; NLR, neutrophil to lymphocyte ratio; TLCO, transfer factor for carbon monoxide.